Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Janknegt

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Expert Opinion on Pharmacotherapy|October 18, 2007
Triptans in the treatment of migraine: drug selection by means of the SOJA methodRobert Janknegt
Expert Opinion on Pharmacotherapy|October 18, 2007
Application of SOJA and InforMatrix in practice: interactive web and workshop toolsRob Brenninkmeijer, Robert Janknegt
Expert Opinion on Pharmacotherapy|October 18, 2007
InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor 'backbones'Gerrit Schreij, Robert Janknegt
Expert Opinion on Pharmacotherapy|October 18, 2007
A prelude to the matrix models supplementMike Scott, Robert Janknegt, Rob Brenninkmeijer
Expert Opinion on Pharmacotherapy|January 7, 2012
InforMatrix: ADP antagonists in acute coronary syndromesRobert Janknegt, Lex Ruiters, Hugo Ten Cate
European Journal of Hospital Pharmacy : Science and Practice|September 13, 2020
Rational selection of inhalation devices in the treatment of chronic obstructive pulmonary disease by means of the System of Objectified Judgement Analysis (SOJA)Robert Janknegt, Johan Kooistra, Esther Metting, et al.
Expert Opinion on Pharmacotherapy|April 9, 2009
InforMatrix for attention deficit hyperactivity disorderRobert Janknegt, Adrianne Faber, Rob Rodrigues Pereira, et al.
Expert Opinion on Pharmacotherapy|October 18, 2007
InforMatrix as an alternative tool in rational and transparent drug-decision makingRob Brenninkmeijer, Jill Mairs, Mark Timoney, et al.
Expert Opinion on Pharmacotherapy|October 18, 2007
System of Objectified Judgement Analysis (SOJA) as a tool in rational and transparent drug-decision makingRobert Janknegt, Mike Scott, Jill Mairs, et al.
Therapeutic Advances in Urology|February 14, 2018
Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of careDavide Meani, Mladen Solarić, Harri Visapää, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|October 18, 2007
Triptans in the treatment of migraine: drug selection by means of the SOJA methodRobert Janknegt
Expert Opinion on Pharmacotherapy|October 18, 2007
Application of SOJA and InforMatrix in practice: interactive web and workshop toolsRob Brenninkmeijer, Robert Janknegt
Expert Opinion on Pharmacotherapy|October 18, 2007
InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor 'backbones'Gerrit Schreij, Robert Janknegt
Expert Opinion on Pharmacotherapy|October 18, 2007
A prelude to the matrix models supplementMike Scott, Robert Janknegt, Rob Brenninkmeijer
Expert Opinion on Pharmacotherapy|January 7, 2012
InforMatrix: ADP antagonists in acute coronary syndromesRobert Janknegt, Lex Ruiters, Hugo Ten Cate
European Journal of Hospital Pharmacy : Science and Practice|September 13, 2020
Rational selection of inhalation devices in the treatment of chronic obstructive pulmonary disease by means of the System of Objectified Judgement Analysis (SOJA)Robert Janknegt, Johan Kooistra, Esther Metting, et al.
Expert Opinion on Pharmacotherapy|April 9, 2009
InforMatrix for attention deficit hyperactivity disorderRobert Janknegt, Adrianne Faber, Rob Rodrigues Pereira, et al.
Expert Opinion on Pharmacotherapy|October 18, 2007
InforMatrix as an alternative tool in rational and transparent drug-decision makingRob Brenninkmeijer, Jill Mairs, Mark Timoney, et al.
Expert Opinion on Pharmacotherapy|October 18, 2007
System of Objectified Judgement Analysis (SOJA) as a tool in rational and transparent drug-decision makingRobert Janknegt, Mike Scott, Jill Mairs, et al.
Therapeutic Advances in Urology|February 14, 2018
Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of careDavide Meani, Mladen Solarić, Harri Visapää, et al.
Pageof 2